

**Table 269.1.** Investigational antiretroviral drugs for HIV infection.

Section	Drug	Target	Class	Company
2a	Rilpivirine (long acting)	HIV-1, treatment and prevention	Long-acting nonnucleoside HIV reverse transcriptase inhibitor	Janssen Therapeutics <sup>a</sup>
2b	Cabotegravir (long acting) (2831265744)	HIV-1, treatment and prevention	Long-acting integrase strand transfer inhibitor	ViiV Healthcare
2c	EFdA MK-8591 (long acting)	HIV-1 and HIV-2 treatment	Long-acting nucleoside analog reverse transcriptase inhibitor	Merck
2d	BMS-986197 (Combivectin)	HIV-1 treatment	Long-acting HIV entry inhibitor	ViiV Healthcare
2e	BMS-955176	HIV-1 treatment	HIV maturation inhibitor	BMS
2f	GSK 2838232	HIV-1, treatment	HIV maturation inhibitor	GSK
2g	Fostemsavir and temsavir	HIV-1 treatment	HIV entry inhibitor	BMS
2h	Cenicriviroc (TAK-652, TBR-652)	HIV-1 treatment	HIV entry inhibitor	Takeda Pharmaceuticals and Tobira Therapeutics
2i	PRO-140	HIV-1 prevention	Monoclonal antibody anti-CCR5 HIV entry inhibitor	CytoDyn
2j	Ibalizumab (TMB-355)	HIV-1 prevention	Monoclonal antibody anti-CD4 HIV entry inhibitor	TaiMed Biologics
2k	3BNC117	HIV-1 treatment and prevention	Broadly neutralizing antibody targeting CD4 binding site on gp120	CellDex Therapeutics
2l	Bictegravir (GS-9883)	HIV-1 treatment	HIV integrase strand transfer inhibitor	Gilead Sciences
2m	Doravirine (MK-1439)	HIV-1 treatment and prevention	HIV nonnucleoside reverse transcriptase inhibitor	Merck
2n	Dapivirine (UAMC01398)	HIV-1 prevention	HIV nonnucleoside reverse transcriptase inhibitor	Janssen Therapeutics

<sup>a</sup>Janssen Therapeutics is a subsidiary of Johnson and Johnson.

**Table 269.2.** Investigational antiviral drugs for hepatitis C virus infection.

Section	Drug	Target	Class	Company
3a	Glecaprevir (ABT-493)	GT-1 to GT-6	NS3/4A protease inhibitor	Abbvie
3b	Pibrentasvir (ABT-530)	GT-1 to GT-6	NS5A assembly inhibitor	Abbvie
3c	Vedoprevir (GS-9451)	GT-1	NS3/4A protease inhibitor	Gilead
3d	AL-335	GT-1 to GT-6	NS5B nucleotide analog RdRp Inhibitor	Alios BioPharma <sup>a</sup>
3e	ACH-3422	GT-1	NS5B nucleotide analog RdRp inhibitor	Achillon
3f	MK-3682(IDX21437)	GT-1 to GT-6	NS5B nucleotide analogue RdRp inhibitor	Merck
3g	MK-8408	GT-1 to GT-6	NS5A assembly inhibitor	Merck
3h	Odalasvir (ACH-3102)	GT-1 to GT-6	NS5A assembly inhibitor	Achillon
3i	Beclabuvir (BMS-791325)	GT-1, GT-3, GT-4, GT-5	NS5B nonnucleotide RdRp inhibitor	BMS
3j	MDV-804 and 845	GT-1 to GT-6	NS5B RdRp NRI	Medivir
3k	Ravidasvir (PPI-668)	GT-1 to GT-6	NS5A assembly inhibitor	Pharco Pharmaceuticals
3l	Voxilaprevir (GS-9857)	GT-1 to GT-6	NS3/4A protease inhibitor	Gilead
3m	Miravirsen	GT-1 to GT-6	MicroRNA-122 inhibitor	Santaris Pharma A/S and Hoffman LaRoche
3n	RG-101	GT-1 to GT-6	MicroRNA-122 inhibitor	Regulus Therapeutics
3o	Alisporivir (Debio-025) and other cyclophilin inhibitors	GT-1 to GT-6	Cyclophilin inhibitor	Novartis

<sup>a</sup>Alios BioPharma and Achillon are now subsidiaries of Johnson & Johnson. Abbreviations: GT: genotype; RdRp: RNA dependent RNA polymerase.